#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cryoglobulinaemia Malignant peritoneal neoplasm Paroxysmal nocturnal haemoglobinuria Sexually transmitted disease Round cell liposarcoma Demyelination X-linked lymphoproliferative syndrome Autoimmune myositis Hereditary angioedema Follicular lymphoma stage I Nephroblastoma Hypochondroplasia Staphylococcal infection Primary mediastinal large B-cell lymphoma Hypereosinophilic syndrome More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Diagnostics Friedreich’s ataxia – Trials in Disease Vascular malformation Aicardi-Goutieres syndrome – Treatment Combined immunodeficiency – Treatment Loeys-Dietz syndrome – Trials in Disease Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Langerhans cell sarcoma Waldenstrom’s macroglobulinaemia recurrent – Life with Disease Activated PI3 kinase delta syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Savolitinib Carfilzomib ARI0008 Regn7257 Naxitamab Brexucabtagene Autoleucel Alx148 Ep0031 Pp1493 Ro7247669 Masitinib Lovo-B Afamelanotide Caplacizumab Testosterone Cobimetinib Belatacept Clobetasol Propionate Biotin Avb-101 More therapies…

    Learn about Your Condition

    Migraine with aura Colorectal cancer stage IV Langerhans cell sarcoma Propionic acidaemia Premature rupture of membranes Respiratory distress Glanzmann's disease Patent ductus arteriosus Aortic valve disease Adrenal insufficiency Giant cell arteritis Neoplasm malignant Rhabdoid tumour of the kidney Premature baby Thymic carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 154, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    • Type 2 diabetes mellitus
    • Cardiovascular disorder
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Carboplatin
    Austria Czechia Denmark France Germany Greece +3

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Doxorubicin Hydrochloride, Liposomal
    • Capecitabine
    France Germany Greece Hungary Italy Poland +1

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Ifinatamab Deruxtecan
    • Docetaxel
    Germany Greece Hungary Italy Poland Spain

  • Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Ifinatamab Deruxtecan
    • Docetaxel
    Germany Greece Hungary Italy Poland Spain

  • Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

    Recruiting

    3 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • Bi 1291583
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

    Recruiting

    3 1
    Investigated Diseases:
    • Autoimmune haemolytic anaemia
    Investigated Drugs:
    • Rilzabrutinib
    Austria Czechia Denmark Germany Greece Hungary +6

  • Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

    Recruiting

    3 1
    Investigated Drugs:
    • IBUZATRELVIR
    • Remdesivir
    Belgium Denmark France Germany Greece The Netherlands +3
Previous Page
1 … 6 7 8 9 10 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!